EXPLORE EVIDENCE
Clinical validation
study results
Confidently identify UIP missed by HRCT with high accuracy
Envisia classifier combined with high resolution CT identified twice as many UIP patients than radiology alone.1
In two independent, prospective multicenter validation trials, Envisia classifier identified UIP with a combined 97% specificity compared to histopathology.1,2
The Envisia Genomic classifier achieved 91% specificity and 63% sensitivity on 144 patients combining two prospective validation cohorts. This performance is retained across gender, age group and smoking status.
Hear from peers
Discover what key opinion leaders are saying about Envisia in case studies, testimonials or on-demand presentations.
References
1. Richeldi L, et al. ATS Journals. Jul 2020.
2. Raghu G, et al. Lancet Respiratory Medicine. Apr 2019.
